Mazdutide

Mazdutide

Mazdutide is an investigational dual agonist targeting both the GLP-1 (glucagon-like peptide-1) receptor and the glucagon receptor, representing a novel dual incretin-glucagon approach to metabolic research. This combined receptor activity is of significant research interest as it aims to harness the complementary metabolic properties of both pathways: GLP-1 receptor activation contributes to appetite suppression, insulin secretion enhancement, and gastric emptying modulation, while glucagon receptor activation promotes hepatic glucose output reduction, lipolysis, and energy expenditure. Research into Mazdutide has focused on its potential applications in obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD), with studies investigating how the dual mechanism may yield superior metabolic outcomes compared to GLP-1 mono-agonism alone. Preclinical and clinical research has explored its effects on body weight reduction, HbA1c levels, and hepatic fat content, with the compound emerging as a subject of growing interest in the metabolic therapeutics research space. Mazdutide represents an important avenue of investigation for researchers studying receptor co-agonism strategies in complex metabolic conditions.